Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 12,170 Shares of Stock

Posted by Stacy Sanders on May 1st, 2026

Clene Inc. (NASDAQ:CLNN – Get Free Report) major shareholder Chidozie Ugwumba sold 12,170 shares of Clene stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $5.63, for a total value of $68,517.10. Following the completion of the transaction, the insider owned 283,305 shares of the company’s stock, valued at approximately $1,595,007.15. This trade represents a 4.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

On Thursday, April 30th, Chidozie Ugwumba sold 5,736 shares of Clene stock. The shares were sold at an average price of $6.08, for a total value of $34,874.88.
On Tuesday, April 28th, Chidozie Ugwumba sold 1,591 shares of Clene stock. The shares were sold at an average price of $5.90, for a total value of $9,386.90.
On Tuesday, April 21st, Chidozie Ugwumba sold 61,345 shares of Clene stock. The shares were sold at an average price of $6.14, for a total value of $376,658.30.
On Monday, April 20th, Chidozie Ugwumba sold 4,318 shares of Clene stock. The shares were sold at an average price of $6.12, for a total value of $26,426.16.
On Friday, April 17th, Chidozie Ugwumba sold 25,040 shares of Clene stock. The shares were sold at an average price of $6.43, for a total value of $161,007.20.
On Thursday, April 16th, Chidozie Ugwumba sold 7,748 shares of Clene stock. The shares were sold at an average price of $6.40, for a total value of $49,587.20.
On Wednesday, April 15th, Chidozie Ugwumba sold 6,374 shares of Clene stock. The shares were sold at an average price of $6.48, for a total value of $41,303.52.
On Thursday, April 2nd, Chidozie Ugwumba sold 24,925 shares of Clene stock. The stock was sold at an average price of $4.81, for a total value of $119,889.25.
On Wednesday, April 1st, Chidozie Ugwumba sold 4,278 shares of Clene stock. The stock was sold at an average price of $4.97, for a total value of $21,261.66.
On Tuesday, February 3rd, Chidozie Ugwumba sold 5,559 shares of Clene stock. The stock was sold at an average price of $4.10, for a total value of $22,791.90.

Clene Trading Up 6.2%

Shares of CLNN stock opened at $6.16 on Friday. Clene Inc. has a twelve month low of $2.28 and a twelve month high of $13.50. The stock has a market capitalization of $72.56 million, a price-to-earnings ratio of -2.37 and a beta of 0.62. The stock has a fifty day simple moving average of $5.68 and a two-hundred day simple moving average of $6.50.

Clene (NASDAQ:CLNN – Get Free Report) last issued its earnings results on Thursday, March 12th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.03 million. Research analysts predict that Clene Inc. will post -1.99 EPS for the current fiscal year.

Institutional Trading of Clene

A number of hedge funds have recently modified their holdings of the stock. Lunt Capital Management Inc. boosted its stake in shares of Clene by 2.5% in the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after buying an additional 1,250 shares during the last quarter. Jones Financial Companies Lllp purchased a new stake in shares of Clene in the third quarter worth about $29,000. Geode Capital Management LLC boosted its stake in shares of Clene by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock worth $482,000 after buying an additional 6,090 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Clene in the second quarter worth about $47,000. Finally, State Street Corp boosted its stake in shares of Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after buying an additional 17,300 shares during the last quarter. Hedge funds and other institutional investors own 23.28% of the company’s stock.

Wall Street Analyst Weigh In

CLNN has been the subject of several recent research reports. Weiss Ratings lowered Clene from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. Canaccord Genuity Group reaffirmed a “buy” rating and set a $48.00 target price on shares of Clene in a research report on Friday, March 13th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $23.00 target price on shares of Clene in a research report on Thursday, March 12th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Clene currently has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Read Our Latest Analysis on Clene

About Clene

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).